New FDA Guidance on Natural History Studies for Rare Diseases
In a recent Ask Cato blog post, I summarized a revised FDA guidance issued in January 2019, Rare Diseases: Common...
Does the FDA Esketamine Approval Open the Door for Enrichment Trial Designs in Psychiatry?
By Greg Hileman, Ph.D, Senior Director of Regulatory Affairs and Principle Regulatory Scientist On March 5, the FDA approved Spravato...
Lets talk about Patient Engagement
Why does everyone talk about “Patient Engagement” in clinical trials? By Shirley Greenfeld Senior Clinical Research Associate As trials are...
Revised FDA Guidance on Developing Rare Disease Therapies
by Kristen Biernat, Ph.D., Scientist Rare diseases, defined as conditions affecting fewer than 200,000 people in the United States, pose...
Pharmacogenetics- Tailoring your product to fit the genes
John received anti-malarial therapy and developed severe hemolytic anemia. He was diagnosed as having G6PD deficiency. Sally was started on...
Draft Guidance of the Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products
By: Juliati Rahajeng, Ph.D., Clinical Strategy Scientist, and Dieanira Erudaitius, Ph.D., Scientist A draft guidance with regards to the formal...
New Year New FDA Strategic Framework on Real World Evidence Program
By Dieanira Erudaitius, Ph.D., Postdoctoral Research Fellow Overview Today there remains an ever-growing ability to generate, collect, and store vast...
Cervical Health Awareness Month – Cervical Cancer: Prevention, Detection, Development
By Amy Lane, Scientist As Cervical Health Awareness Month comes to a close, it is a good time to review...
Stay on the Safe Side- Reference Safety Information – Europe
Aside from New Year’s resolutions and a clean sweep, what else should you refresh in 2019? I politely suggest your...
Combination immunotherapy: The latest revolution in cancer treatment
An analysis of the clinical landscape The present focus in the treatment of cancer is immunotherapy, in particular immunotherapies that...